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Corporation, Diagnostic Platform, Washington, DC, USAA B S T R A C TBackground: Health technology assessments (HTAs) are increasingly
used to inform coverage, access, and utilization of medical technol-
ogies including molecular diagnostics (MDx). Although MDx are used
to screen patients and inform disease management and treatment
decisions, there is no uniform approach to their evaluation by HTA
organizations. Objectives: The International Society for Pharmacoe-
conomics and Outcomes Research Devices and Diagnostics Special
Interest Group reviewed diagnostic-specific HTA programs and iden-
tified elements representing common and best practices. Methods:
MDx-specific HTA programs in Europe, Australia, and North Amer-
ica were characterized by methodology, evaluation framework, and
impact. Published MDx HTAs were reviewed, and five representa-
tive case studies of test evaluations were developed: United King-
dom (National Institute for Health and Care Excellence’s
Diagnostics Assessment Programme, epidermal growth factor
receptor tyrosine kinase mutation), United States (Palmetto’s
Molecular Diagnostic Services Program, OncotypeDx prostate can-
cer test), Germany (Institute for Quality and Efficiency in Health-
care, human papillomavirus testing), Australia (Medical Services
Advisory Committee, anaplastic lymphoma kinase testing foree front matter Copyright & 2016, International S
r Inc.
.1016/j.jval.2016.02.012
rfield@gmail.com.
ndence to: Susan Garfield, 24 Sherman Bridge Roanon–small cell lung cancer), and Canada (Canadian Agency for
Drugs and Technologies in Health, Rapid Response: Non-invasive
Prenatal Testing). Results: Overall, the few HTA programs that have
MDx-specific methods do not provide clear parameters of accept-
ability related to clinical and analytic performance, clinical utility,
and economic impact. The case studies highlight similarities and
differences in evaluation approaches across HTAs in the perform-
ance metrics used (analytic and clinical validity, clinical utility),
evidence requirements, and how value is measured. Not all HTAs
are directly linked to reimbursement outcomes. Conclusions: To
improve MDx HTAs, organizations should provide greater trans-
parency, better communication and collaboration between industry
and HTA stakeholders, clearer links between HTA and funding
decisions, explicit recognition of and rationale for differential
approaches to laboratory-developed versus regulatory-approved
test, and clear evidence requirements.
Keywords: diagnostics, health technology assessment.
Copyright & 2016, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Health technology assessment (HTA) is “the systematic evalua-
tion of the properties and effects of a health technology, address-
ing the direct and intended effects…as well as its indirect and
unintended consequences…aimed mainly at informing decision
making regarding health technologies” [1]. Many health caresystems have established HTA programs to inform clinical and
coverage decision making for medical technologies. HTA pro-
grams are most advanced for pharmaceuticals; however, few
systems have established processes specifically delineated for
molecular diagnostics (MDx) [2–4]. MDx influence many health
care decisions including screening, diagnosis, medical treatment,
and prevention [5]. Some HTA programs are taking existingociety for Pharmacoeconomics and Outcomes Research (ISPOR).
d, Wayland, MA 01778.
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MDx with little modification of process or requirements [3,4,6,7].
An example of this can be seen in Canada’s Alberta Health
Technologies Decision Process, which considers three main
components in its HTA process: Social Systems and Demo-
graphics; Technology Effects and Effectiveness; and Economic
Considerations. The process includes a systematic literature
review, in some cases a meta-analysis of data, and comments
on the quality of the evidence supporting the efficacy, safety, and
risk of adverse events [8,9]. In contrast, other HTA groups, such as
the National Institute for Health and Care Excellence (NICE)’s
Diagnostic Assessment Programme (DAP) in the United Kingdom
[10], Palmetto’s Molecular Diagnostic Services (MolDXs) Program
for MDx in the United States [6], have developed specific evalua-
tion frameworks for MDx. As well, the Canadian Agency for Drugs
and Technologies in Health (CADTH) uses an evaluation frame-
work applicable to medical devices, diagnostic tests, and medical,
dental, or surgical procedures and programs [11].
The objective of this article was to compare several molecular
diagnostic HTA programs, describe examples of molecular diag-
nostic HTAs conducted, and make recommendations to improve
and standardize systems moving forward. As part of that process,
case studies of four diagnostic HTAs from the United Kingdom, the
United States, Germany, and Australia are presented to demon-
strate current practices, describe diagnostic attributes being eval-
uated, and highlight the challenges that need to be overcome for
an optimal molecular diagnostic HTA framework to be realized.
The recommendations are targeted toward policy decision makers,
payers, health technology assessors, and industry members.Methods
The Medical Devices and Diagnostics (MD&D) Special Interest
Group (SIG) of the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) was established in 2013.
Researchers experienced in this field and working in academia,
research organizations, the diagnostics industry, or US or Euro-
pean governments were invited to join the leadership committee
of the MD&D SIG. The leadership committee conducted this
review across multiple European countries, Australia, and North
America. We identified the five health care systems with estab-
lished MDx evaluation programs and where a detailed descrip-
tion of the program is publicly available. From this process,
Australia’s Medical Services Advisory Committee (MSAC) [12],
Canada’s CADTH [11], UK’s NICE [10], US’s Evaluation of Genomic
Applications in Practice and Prevention (EGAPP) [13] and Palmet-
to’s MolDX Program [6], and Germany’s Institute for Quality and
Efficiency in Healthcare (IQWiG) [14] were identified. First, the
programs were assessed on the basis of1. the program’s domain of influence;
2. the purpose of assessment;
3. elements included in the analysis (i.e., product descriptions,
clinical effectiveness measures, ethical issues, etc.);
4. inclusion of safety measures;
5. what type of data were included in their analyses;
6. how levels of evidence were evaluated; and
7. whether economics are included in the evaluation.
Then, each program was characterized using the following
domains: country, purpose, health problem and current use of
technology, description and technical characteristics of technol-
ogy, population, safety, accuracy and clinical validity, clinical
effectiveness, patient preferences, quality of evidence, costs and
economic impact, ethical, legal, and social aspects, organizational
aspects, environmental factors, and levels of evidence (Table 1).Together these factors illustrate the programs’ relative market
impact, complexity, transparency, comprehensiveness, and flex-
ibility of the HTA programs for MDx.
There was no single MDx whose assessment was publicly
available across all HTA programs included in the study. There-
fore, case studies were developed to illustrate the current eval-
uation processes and challenges for HTA of MDx. We selected
recently completed MDx assessments within the systems
included in the study and required that detailed descriptions of
the assessments were publicly available. The intent of the case
studies was not to comprehensively describe the features of all
health care systems with HTA processes for diagnostics, nor
summarize MDx that have been evaluated to date. Instead, the
case studies demonstrate the process and outcomes from four
representative assessments. These include Palmetto’s MolDx
evaluation of OncotypeDX prostate cancer test, NICE DAP’s
assessment of epidermal growth factor receptor tyrosine kinase
(EGFR-TK) testing, IQWiG’s assessment of human papillomavirus
(HPV) testing, MSAC’s evaluation of anaplastic lymphoma kinase
(ALK) gene testing for non–small cell lung cancer (NSCLC), and
CADTH’s Rapid Response on non-invasive prenatal testing (NIPT).
Overall, there are very few MDx HTAs that are clearly described
in process and outcome available in the public domain. Because
not all reviews are publicly available, the cases may fall short of
true representation and generalizability. However, as case studies
they provide context and demonstrate the organization’s practices.
Current Practices and Processes for Evaluation of Diagnostics
Table 1 presents the characteristics of the five health care systems
for evaluation of MDx included in this review. Although there are
some commonalities across programs, there is no one standard HTA
process to evaluate MDx [2,3]. We also recognize that the MDx field is
relatively new, and professional associations, such as the Association
for Molecular Pathology and the American College for Medical
Genetics and Genomics, are developing guidance for best practices.
As illustrated in Figure 1, the relationship between the HTA organ-
izations, government, and other payers, the level of transparency of
the process, and the specific processes and methods (e.g., types of
studies considered and level of evidence) differ across the programs.
Key differences that create heterogeneity include the following:1. There is no clear mandate as to which diagnostics need
formal HTA (i.e., the vast majority of in vitro diagnostics do
not undergo a formal national or regional HTA).2. There is no uniform approach for laboratory-developed tests
(LDTs; also called “in-house” or “home-brew” tests): Whether
they should be formally evaluated by HTA agencies along with
regulatory-approved tests, or whether payers should consider
them differently with regard to pricing and reimbursement.3. Evidence requirements are not clearly delineated with no
universal guidance for outcomes to be measured, appropriate
study types, performance requirements, comparative effec-
tiveness, and economic thresholds.4. The impact of HTA recommendations on reimbursement,
access, and pricing is often unclear and varies substantially
across health care systems [2].5. It is unclear how criteria assessed in HTA translate into molec-
ular diagnostic pricing and reimbursement decision making.
These and other differences make it not only difficult to know
a priori whether a diagnostic will be subject to HTA but also
whether the evidence is sufficient to reach reimbursement
decisions. Although HTA professionals are working toward estab-
lishing evaluation standards that promote quality and access,
diagnostic industry members are ultimately trying to understand
the pathways to predictably obtain reimbursement.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 5 7 7 – 5 8 7 579Although analytical and clinical validity, clinical utility, and cost
or cost-effectiveness of the technology for the target population are
common parameters considered by all systems, the ways these
measures are defined and leveraged within evaluations varies
across agencies and across different stakeholder types (e.g., physi-
cians, payers, HTA agencies, and laboratory directors). Analytical
validity refers to how well the test predicts the presence or absence
of a particular biomarker of interest, whereas clinical validity refers to
how well the genetic variant being analyzed is related to the
presence, absence, or risk of a specific disease. Clinical utility
assesses whether the test can provide information about diagnosis,
treatment, management, or prevention of a disease that will impact
clinical decision making and outcomes [15].
Within the programs evaluated, there are no explicit or
common methods on how payers evaluate data on analytic and
clinical validity and clinical utility. In addition, these are not the
only factors considered in making HTA and ultimately reim-
bursement decisions [16]. The MSAC [12], the EGAPP [13], and the
CADTH [11] also incorporate ethical, legal, social, familial, envi-
ronmental, and/or organizational elements in their evaluation. In
the United Kingdom, NICE’s DAP focuses on clinical and perform-
ance metrics, cost-effectiveness, and the patient care pathway
from testing to treatment [10]. The MSAC [12], NICE’s DAP [10],
the EGAPP [13], and the CADTH [11] produce recommendations to
stakeholders primarily on the basis of assessment of the avail-
able evidence. Where evidence gaps exist, expert opinions may
be solicited; this approach is used by Palmetto’s MolDX Program
in the United States [17].
Variation exists in submission format as well as the timelines
associated with review. For example, the DAP has well-defined
requirements for assessment and does not require an extensive
submission document, though the timeline is long, taking more
than 2 years in some cases (e.g., MammaPrint, Oncotype DX, IHC4,
and Mammostrat). It requires manufacturers to address a range of
comments from different stakeholders, additional data needs, and/
or clarifications throughout the process [18].
Industry members and other agencies have recognized the
challenges in current molecular diagnostic HTA approaches, and
begun work to address them via multistakeholder working
groups. For example, European network for health technology
assessment is working to create pan–European Union standards
that specifically address some of these issues; however, gaining
buy-in from all stakeholders has been challenging [2]. This is
similar to dialogue related to evidence standards for diagnostics
that has occurred in some systems such as France, the United
Kingdom, and the United States.
The significant variations led the MD&D SIG to question how
these HTAs are playing out in the real world. The following case
studies provide insights into how organizations are structuring
diagnostic evaluations and examples of how each process is
being applied in the real world. The case studies include Palmet-
to’s assessment of OncotypeDx for prostate cancer in the United
States, EGFR-TK assessment in the United Kingdom by NICE’s
DAP, IQWiG’s assessment of HPV testing in Germany, MSAC’s
assessment of ALK testing for NSCLC in Australia, and CADTH’s
Rapid Response on NIPT in Canada. For each case study, we
present the background about the HTA program and test eval-
uated, evaluation parameters, and the assessment outcome and
its justifications.
The Case of Oncotype DX Prostate Cancer Assay Assessment
by Palmetto’s MolDX Program in the United States
Background of the HTA program and test evaluated
Medicare, the largest US payer, responded to the rapid growth of
MDx, companion diagnostics, and personalized medicines in
clinical practice in the recent decades by authorizing PalmettoGBA to develop a system for HTA, pricing, and reimbursement for
diagnostics [17]. Palmetto’s MolDX Program was implemented in
2012 and conducts HTAs on both US Food and Drug Administration–
approved diagnostics and LDTs. The goals of the program are 1)
focusing Medicare coverage to diagnostics that demonstrate clinical
validity and utility; 2) tracking utilization for reimbursement
through the implementation of unique codes for each diagnostic;
3) creating a consistent and standardized approach for making
coverage and pricing decisions for diagnostics; and 4) building a
body of evidence demonstrating the effectiveness of diagnostics in
the real-world setting by linking specific tests with clinical decision
making and patient outcomes [16,17]. Tests are not reimbursed until
a favorable decision is reached.
The criteria for coverage decision making are publicly avail-
able; however, the specific evidence reviewed and how coverage
decisions are made is not fully transparent (e.g., information
considered confidential and/or proprietary may be omitted) and
can vary substantially from test to test. In the case of the
Oncotype DXs Prostate Cancer Assay, Palmetto conducted a
formal review that established positive coverage via a local
coverage determination in late 2015.
The test is a prostate biopsy–based 17-gene reverse-tran-
scriptase polymerase chain reaction assay, representing four
molecular pathways (androgen signaling, cellular organization,
stromal response, and proliferation), that provides a biologic
measure of cancer aggressiveness. It is indicated for men who
are considered candidates for active surveillance and is designed
to inform decisions between AS and immediate treatment.
Evaluation parameters
The clinical performance of the assay was assessed leveraging
data from a prospective-retrospective study of 395 patients with
National Comprehensive Cancer Network (NCCN) very low-, low-,
and intermediate-risk disease with the objective to determine
whether the test results added independent predictive informa-
tion beyond standard clinical and pathologic data as to whether
the patient was likely to progress. In multivariable analysis, the
Oncotype DX(R) Genomic Prostate Score (GPS) was found to
predict adverse pathology at radical prostatectomy and allow
more patients for active surveillance when used with NCCN
criteria. The second study, a multicenter longitudinal assessment
of 402 men, looked at tumor aggressiveness. It demonstrated that
the test predicted biochemical recurrence, adverse pathology,
and metastatic recurrence (though rare).
Assessment outcome
As a result of these study findings, Palmetto (via the MolDx
Assessment Program) found that the “potential usefulness of this
test is that it allows physicians to determine which patients with
early prostate cancer are candidates for active surveillance and
are more likely to have a good outcome without needing to
receive definitive treatment” [19]. The assessment directly
informed the development of a Local Coverage Determination
for Medicare, leading to test reimbursement. However, criteria for
coverage included use within a defined patient subset and that
ordering clinicians must have completed a training/certification
program in order to use/bill for/and get reimbursed for the test.
This last requirement is perhaps an interesting foreshadowing of
HTA agencies understanding that the value of many MDx is
influenced by how and for whom they are used.
In the case of this test, evidence of clinical utility was
supplemented by recommendation within an evidence-based
clinical practice guideline (e.g., NCCN), which frequently weighs
heavily into evaluation outcomes. Table 2 provides additional
examples of MDx that Palmetto recently reviewed and resulting
coverage decisions.
Table 1 – Diagnostic technologies assessment evaluation frameworks.
Domain MSAC [12] NICE DAP [10] EGAPP [13] CADTH HTERP [11] Palmetto GBA
MolDX [6]
IQWiG [14]
Country Australia United Kingdom United States Canada United States Germany
Purpose  To advise the Australian
Minister for Health and
Ageing on evidence
relating to the safety,
effectiveness, and cost-
effectiveness of new
medical technologies
and procedures
 To evaluate diagnostic
technologies that have the
potential to improve health
outcomes but whose
introduction is likely to be
associated with an overall
increase in cost to the NHS
 To formulate
recommendations for genetic
tests and other genomic
applications for health care
providers, public health
practitioners, policymakers,
and consumers using an
evidence-based approach
 To develop guidance and/or
recommendations on
nondrug health technologies
for a range of stakeholders
within the Canadian health
care system using evidence-
based and a multicriteria
framework
 To identify and
establish
coverage and
reimbursement
for molecular
diagnostic tests
 To evaluate benefits, harms,
and economic implications
of interventions: To support
the Federal Joint Committee
(G-BA) and the National
Association of Statutory
Health Insurance Funds in
fulfilling their legal duties
Health problem
and current
use of
technology
 Intended role of index
test and intended use
of test
 Care pathway, including
sequence of tests and
treatments, outcomes and
costs, and other
considerations
 Potential public health
impact based on prevalence/
incidence of the disorder,
prevalence of the gene
variants, or number of
individuals likely to be
tested, test availability in
clinical practice, and other
practical considerations
 Background on health
condition
 Issue and policy question(s)
 Intended
purpose
 Potential benefits of medical
interventions
 Patient-centered health
information
 Description
and technical
characteristics
of technology
 Proposed function and
technical aspects
of tests
 Details about technology and
comparators provided
 Current options for
diagnosis/screening
regulatory status in
Canada, etc.
 Alternative diagnostic
technologies that address
the same issue
 Description
of assay
 Description of the
intervention
Population  Incidence, prevalence,
and natural history of
target condition
 Description of potential
impact of test on patient
mobility and mortality,
activities of daily living,
and quality of life
 Patient characteristics,
conditions to be diagnosed,
and etiologies of the
conditions
 Prevalence/ incidence of the
disorder, prevalence of gene
variation, number of
individuals likely to be tested
 The availability of
interventions for individuals
with a positive test result or
their family members
 Size of affected population  Intended
patient
population(s)
 Intended patient
population(s)
Safety  Safety of index test vs.
comparator
 Significant adverse effects
and test preparation effects
 Safety in absolute terms,
and in comparison to
comparators
 Optional
Accuracy and
clinical
validity
 Assessment of clinical
validity
 Assessment of clinical
validity
 Assessment of analytic and
clinical validity
 Assessment of analytic and
clinical validity
 Assessment of
analytic and
clinical validity
 Assessment of analytic and
clinical validity
Clinical
effectiveness
 Assessment of clinical
utility
 Assessment of clinical utility  Assessment of clinical utility  Assessment of clinical utility  Assessment of
clinical utility
 Assessment of clinical utility
Patient
preferences
 Acceptability of test by the
patient
Quality of
evidence
 QUADAS tool  QUADAS tool  Involves the adequacy of
each evaluation component
(analytical validity, clinical
validity, and clinical utility):
low, medium, high
 QUADAS tool
V
A
L
U
E
IN
H
E
A
L
T
H
1
9
(2
0
1
6
)
5
7
7
–
5
8
7
580
Costs and
economic
impact
 Cost-effectiveness  Cost-effectiveness
considered
 Costs of tests, follow-up
testing, treatment, treatment
of adverse effects from test
or treatment, and monitoring
needed before or after the
treatment
 Modeling to measure and
value health effects for
diagnostic assessments can
be conducted
 Cost-effectiveness  Cost-effectiveness
 Cost of tests, equipment,
personnel, consumables,
and maintenance
 Availability of evidence of
value for money
 Expected lifespan and total
budget impact of the test
 Price
determination
occurs for
diagnostic tests
that meet the
Medicare
criteria for
coverage
 Cost of special
equipment,
labor, and
supplies, such
as reagents
 Cost-effectiveness and
budget impact analysis
 Direct costs and resource use
 Indirect costs (loss of
productivity) potentially
considered on cost side
Ethical, legal,
and social
aspects
 Ethical and legal aspects
related to test, and
ethical, legal, and social
stakes related to
genetic tests
 Potential psychological
and social impacts of
this test on patient
or family
 Familial, ethical, societal, or
intermediate outcomes
considered sometimes
 Societal perspectives on
whether use of the test in
proposed clinical scenario is
ethical and reviewed before
evidence review
 Ethical, legal, and social
issues such as patient access
to the test in Canada, patient
access to proper
interpretation of the results,
support, and follow-up
 Optional
Organizational
aspects
 Accessibility limits for
test, information on
molecular test
accessible to health care
professionals and
public, and availability
and accessibility of
professional services
 Integration of test into
routine practice
 Integration of test into
existing workflow
 Training/competency
requirements
 Repair and maintenance
Environmental
factors
 Environmental impact
of test
Levels of
evidence
 The ranking of studies
by “levels” of evidence
on the basis of type of
study design
A systematic review of
Level 2 studies
 These include RCTs,
non-randomized
experimental trial,
cohort study, case-
control, time series,
case series with either
post-test or pretest/
post-test outcomes
 Evidence is searched for
studies that follow patients
from testing, through
treatment, to final outcomes
(e.g., systematic reviews,
RCTs, cohort studies, and
observational studies)
 Data test accuracy studies
reviewed
 Models of the management
or treatment of the condition
after diagnosis explored.
Expert opinion or expert
elicitation may be used to
provide a parameter value
for model(s), or model(s) can
be redesigned to use other
parameters
 The hierarchies of data
sources for analytic validity,
and of study designs for
clinical validity and utility,
designated for all as Level 1
(highest) to Level 4
 Data sources include meta-
analyses of RCTs, controlled
trials, longitudinal cohort,
cohort, case-control, and
cross-sectional studies,
unpublished and/or non–
peer-reviewed research,
clinical laboratory or
manufacturer data,
consensus guidelines, and
expert opinion
 The hierarchy of evidence
for diagnostic test studies
 Data sources include
bibliographic databases,
guideline databases, hand
searching in selected
scientific journals, contacts
with experts/industry/
patient organizations,
publicly accessible
documents from regulatory
authorities
CADTH, Canadian Agency for Drugs and Technologies in Health; EGAPP, Evaluation of Genomic Applications in Practice and Prevention; HTA, health technology assessment; HTERP, Health
Technology Review Panel; IQWiG, Institute for Quality and Efficiency in Health Care; MSAC, Medical Services Advisory Committee; MolDX, Molecular Diagnostic Services Program; NHS, National
Health Service; NICE DAC, National Institute for Health and Care Excellence Diagnostics Advisory Programme; QUADAS, Quality Assessment of Diagnostic Accuracy Studies; RCTs, randomized
controlled trials.
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Fig. 1 – Current HTA Programs for Molecular Diagnostics. CADTH, Canadian Agency for Drugs and Technologies in Health;
EGAPP, Evaluation of Genomic Applications in Practice and Prevention; HTA, Health technology assessment; HTERP, Health
Technology Review Panel; MSAC, Medical Services Advisory Committee; NICE DAP, National Institute for Health and Care
Excellence Diagnostics Advisory Programme.
Table 2 – Diagnostics illustrative MDx Palmetto local coverage determinations.
Test reviewed (LCD) Coverage
decision
Select coverage guidance excerpt
Circulating Tumor Cell (CTC)
Marker Assays (L34631) [32]
Noncoverage Although detection of elevated CTCs during therapy is a definitive indication of
subsequent rapid disease progression and mortality in [different cancers], no data
have been forthcoming to demonstrate improved patient outcomes, or that the assay
changes physician management to demonstrate improved patient outcomes.
NRAS Genetic Testing (L34627)
[33]
Limited coverage Palmetto GBA will cover NRAS testing for metastatic colorectal cancer, per NCCN
guidelines (Version 3.2014). All other NRAS testing is noncovered.
 Colorectal cancer: The 2013 NCCN Colorectal Practice Guidelines for Colon Cancer
describe a recent study which reported that 17% of 641 patients from the PRIME trial
without KRAS exon 2 mutations were found to have mutations in exons 3 and 4 of KRAS
or mutations in exons 2, 3, and 4 of NRAS. A predefined retrospective analysis of a
subset of these patients showed that progression-free survival and overall survival
were decreased in those who received panitumumab plus FOLFOX compared to those
who received FOLFOX alone. NCCN Colorectal Guidelines (Version 3.2014) recommend
“All patients with metastatic colorectal cancer should have tumor tissue genotyped for
RAS mutations (KRAS and NRAS). Patients with any known KRAS mutation or NRAS
mutation should not be treated with either cetuximab or panitumumab.” Consequently,
Palmetto GBA is expanding coverage of NRAS to patients with metastatic colorectal
cancer.
 Melanoma: The prognostic significance is still not well understood and further
investigation of the histologic types with specific NRAS mutations in a larger series is
necessary to validate these apparent impacts on patient outcomes.
Infectious Disease Molecular
Diagnostic Testing (L31747) [30]
“Full” coverage Molecular diagnostic testing, which includes deoxyribonucleic acid (DNA)- or
ribonucleic acid (RNA)-based analysis, with or without amplification/quantification,
provides sensitive, specific, and timely (i.e., relative to that of traditional culture-
based methods) identification of diverse biological entities, including microorganisms
and tumors.
A standardized nucleic acid probe reacts directly with nucleic acids in the test sample.
This format is termed a Nucleic Acid Test (NAT). If the test sample contains the
organism of interest, the reaction (e.g., hybridization) of these elements will create a
detectable end point.
ConfirmMDx Epigenetic Molecular
Assay (L35368) [34]
Coverage with
evidence
development
Limited coverage is provided for the ConfirmMDx epigenetic assay for prostate cancer to
reduce unnecessary repeat prostate biopsies. While prospective evidence is currently
being generated, retrospective evidence of clinical utility supports the potential value
of this diagnostic test and serves as adequate evidence of likely clinical utility to
support limited coverage. Palmetto GBA is aware that MDxHealth has initiated the
PASCUAL Clinical Trial to prospectively address outcomes to establish clinical utility.
While patient participation in the PASCUAL trial is not a prerequisite to the limited
coverage, coverage is limited to providers enrolled in the ConfirmMDx Certification
and Training Registry program.
The performance of this assay in a large, blinded clinical validation study demonstrated
an NPV of 90%, which is considerably higher than that afforded by standard
histopathology review. A mathematically based budget impact model using the assay
in urologic practices to decide upon the need for repeat biopsies reported significant
cost and medical resource savings by avoiding unnecessary, invasive biopsies over
current standard of care methods.
LCD, local coverage determination; MDx, medical diagnostics.
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Testing for Predicting Response to First-Line Tyrosine Kinase
Inhibitor Drugs in Advanced NSCLC
Background of the HTA program and test evaluated
The DAP is part of NICE’s program to evaluate medical technol-
ogies, and is leveraged for evaluating complex diagnostic tests on
the “basis of clinical utility and cost-effectiveness analysis or
where meaningful assessment requires the consideration of
multiple technologies or indications” [10]. MDx that have the
potential to improve health outcomes at an increased cost to the
system are within the domain of evaluation. In 2012, the DAP
conducted its first assessment of MDx, EGFR-TK mutation testing
for predicting erlotinib and gefitinib response in advanced NSCLCTable 3 – Tests/methods appraised and in use in the UK
Tests/methods Data co
Therascreen EGFR RGQ PCR Kit (CE-marked* real-time PCR)  RCT ut
 Publish
technic
perform
 Labora
 Expert
Therascreen EGFR Pyro Kit (CE-marked* pyrosequencing)  Labora
 Expert
Cobas EGFR Mutation PCR Test (CE-marked* real-time PCR)  RCT ut
 Labora
 Expert
Pyrosequencing AND fragment length analysis (FLA)  Labora
 Expert
Single-strand conformation polymorphism analysis  Labora
 Expert
High-resolution melt analysis  Labora
 Expert
Next-generation sequencing  Labora
 Expert
Direct (Sanger) sequencing of exons 19–21 only  RCT ut
 Expert
Direct (Sanger) sequencing of exons 18–21 only  RCTs
 Expert
Sanger sequencing of samples for NSCLC samples with
430% tumor cells OR Cobas EGFR Mutation PCR Test for
samples with o30% content
 RCTs (
 Labora
 Expert
Sanger sequencing of samples for NSCLC samples with
430% tumor cells OR Therascreen EGFR Mutation PCR
Test for samples with o30% content
 RCTs (
 Expert
Sanger sequencing followed by FLA AND real-time PCR (RT-
PCR) of negative samples
 RCTs (
 Labora
 Expert
CE, XX; PCR, polymerase chain reaction; NHS, National Health Scheme; N
* CE-marked, regulatory approved.[20]. In 2009, NICE had recommended erlotinib and gefitinib for
first-line use in NSCLC and EGFR-TK mutation testing was
included in the assessment [21,22], but a review of different
testing approaches was not conducted.
Evaluation parameters
The assessment of EGFR-TK testing included both regulatory-
approved (i.e., CE marked) and nonregulatory-approved LDTs,
and alternative testing strategies using two or more test types. In
contrast to NICE drug appraisals that evaluate whether specific
drugs should be used, the EGFR-TK was assessed on the premise
that testing should be and is already being done with the central
question being which test should be used. Testing approaches
included in the assessment are presented in Table 3.NHS.
nsidered Decision analytic
model
approach(es)
Outcome
ility data
ed UK
al
ance study
tory survey
opinion
 Comparative
effectiveness
 Linked evidence
 Assumption of
equal
prognostic value
Recommended
tory survey
opinion
 Assumption of
equal
prognostic value
Insufficient evidence for
recommendation
ility data
tory survey
opinion
 Assumption of
equal
prognostic value
Recommended
tory survey
opinion
 Assumption of
equal
prognostic value
Insufficient evidence for
recommendation
tory survey
opinion
 Assumption of
equal
prognostic value
Insufficient evidence for
recommendation
tory survey
opinion
 Assumption of
equal
prognostic value
Insufficient evidence for
recommendation
tory survey
opinion
 Assumption of
equal
prognostic value
Insufficient evidence for
recommendation
ility data
opinion
 Comparative
effectiveness
 Linked evidence
 Assumption of
equal
prognostic value
Not in scope
opinion
 Linked evidence
 Assumption of
equal
prognostic value
Recommended only in
combination with other
tests (see table rows below)
Sanger only)
tory survey
opinion
 Assumption of
equal
prognostic value
Recommended
Sanger)
opinion
 Assumption of
equal
prognostic value
Recommended
Sanger)
tory Survey
opinion
 Assumption of
equal prognostic
value (FLA/RT-PCR)
Recommended
SCLC, non–small cell lung cancer; RCT, randomized controlled trial.
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noteworthy approaches for collection of the evidence to support
usefulness of diagnostics, including the following:1. Acceptance of “real-world” observational evidence (e.g.,
patient registry studies) rather than experimental data exclu-
sively. In addition to reviewing available data identified in a
systematic review, the DAP
○ performed a Web-based survey on test performance and
use in 13 laboratories in the United Kingdom and
○ supported retrospective evidence collection using archived
tissue samples to link test performance to patient
outcomes.2. Cost-effectiveness was assessed using different decision ana-
lytic approaches depending on data available for each test
type/testing strategy (see Table 3 for details) [20].
○ “Comparative effectiveness” approach for tests with
progression-free survival or overall survival data, which
reflects clinical utility;
○ “Linked evidence” approach (i.e., indirect correlation of test
use with overall outcomes that include treatment efficacy)
for tests with data on accuracy for predicting drug
response, which reflects clinical validity; and
○ For tests that are not amenable to the other two
approaches, “assumption of equal prognostic value”
approach is used; this involves collecting test performance
data via a provider survey.3. Clinical and cost-effectiveness evidence evaluated in the 2009
assessment of gefitinib (in combination with EGFR-TK muta-
tion testing) [22].
In contrast to HTA programs for diagnostics in other countries
(e.g., Australia [MSAC], Canada [CADTH, Ontario Health Technol-
ogy Advisory Committee], United States [Palmetto]) [23–25], the
DAP demonstrated some flexibility in considering a range of
evidence including indirect comparisons and linked-evidence
analyses to compare tests on the basis of modeled patient
outcomes and costs [20]. The DAP, however, concluded that
assumptions made on comparative effectiveness used in these
models were unlikely to hold true due to potential differences in
the populations of the compared trials. Furthermore, the DAP
concluded that results of the cost-effectiveness analyses were
not sufficiently robust because of uncertainty in input costs and
overall survival estimates.
The appraisal of EGFR-TK mutation tests highlights the
difficulty in robust comparative cost-effectiveness analysis for
diagnostics due to evidence requirements that are largely diver-
gent and unclear on a global scale. This led to limited availability
of direct comparisons, and uncertainties surrounding clinical
utility, which is largely determined by the pharmacological treat-
ment effect rather than testing strategies [24,26].
Assessment outcome
The outcome of the assessment was that EGFR mutation testing
is worthwhile and both commercially available tests (Roche’s
cobas and QIAGEN’s therascreen) and the reference test (Sanger
Sequencing) can be used.
The Case of HPV Testing for Cervical Cancer Screening in
Germany, Assessed by IQWiG
Background of the HTA program and test evaluated
In Germany, HTA submissions for diagnostics are usually not
required for reimbursement. Only screening tests are required to
be formally assessed before receiving reimbursement in the
outpatient setting, which is determined by the Einheitlicher
Bewertungsmaßstab [14]. In February 2010, the relevant HTAagency, IQWiG, evaluated HPV DNA testing as a possible addition
or replacement to cytology for primary screening of women for
cervical cancer.
Evaluation parameters
In its evaluation, the IQWiG reviewed randomized controlled
multicenter studies with parallel groups; its decision was made
in November 2011 [27]. The factors considered included the
following:1. overall survival;
2. disease-specific (tumor-specific) survival;
3. invasive cervical cancer;
4. high-grade cervical intraepithelial dysplasia or in situ cervical
cancer (CIN3/CIS);
5. composite outcome of CIN3/CIS and invasive cervical cancer;
6. direct and indirect harms from screening; and
7. health-related quality of life, including psychosocial aspects.
Supplementary information considered included the
following:1. moderate-grade cervical intraepithelial dysplasia;
2. composite clinical outcome of CIN3/CIS and invasive cervical
cancer;
3. sensitivity and specificity of the test; and
4. clinical ramifications and resource use after an initial positive
test result.
Assessment Outcome
The assessment concluded that although there was an “indica-
tion of a benefit” of a screening strategy including HPV testing
alone or in combination with cytology-based testing versus a
screening strategy including cytology-based testing alone, the
potential harm from HPV testing alone or in combination with
cytology-based testing could not be assessed because of a lack of
data. As a result, HPV testing was not reimbursed for primary
screening in Germany.
Since the original assessment, several large studies have been
published addressing some of the concerns discussed above
[28,29]. In addition, the US Food and Drug Administration
approved one HPV test for primary screening in April 2014. In
October 2013, the IQWiG initiated another assessment of HPV
testing; a so-called Rapid Report was issued in June 2014 [35]. No
studies were identified or included that had not already been
included in the first assessment. Nonreimbursement was again
the decision because “There are still no data or no evaluable data
available on mortality, quality of life and potential harm.”
Case of the Australian MSAC’s Review of ALK Gene
Arrangement Testing in Patients with NSCLC to Determine
Eligibility for Treatment with Crizotinib
Background of the HTA program and test evaluated
The MSAC is an independent expert committee that evaluates
new technologies on the basis of clinical and cost-effectiveness,
and considers “the circumstances under which public funding
should be supported” [12]. Abbott Molecular and Pfizer Australia
(the applicant) submitted to the Australian Department of Health
in June 2013 a joint proposal requesting public funding for
fluorescence in situ hybridization (FISH) testing for ALK gene
rearrangement status in patients with NSCLC. Crizotinib, a novel,
targeted anticancer agent developed by Pfizer, is indicated for the
treatment of patients with a confirmed ALK gene expression as a
second- or third-line treatment option.
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The committee reviewed the proposed clinical protocol, the
clinical data to support it, and the population eligible for testing
[36]. The applicant proposed both expanding the test-eligible
population to include patients with squamous cell tumor pathol-
ogy and not restricting to patients with wild-type EGFR status:
both are proposed descriptors that the MSAC felt could allow
“leakage of testing” to patients where the proposed benefits of
crizitonib are not well supported.
The applicant proposed a two-step process wherein patients
would first be triaged with an ALK immune-histochemical (IHC)
staining of tumor tissue before proceeding to the ALK-FISH diag-
nostic. Although the MSAC acknowledged that IHC staining is
justified as a triage test (there was seen to be low likelihood of
patients missing out on crizotinib because of an inaccurate IHC
result), the MSAC expressed concern about the appropriate level of
“signal” to proceed to ALK-FISH testing. The MSAC, in its review
document, wrote that “the numbers and costs of ALK gene arrange-
ment testing would increase if the extent of overexpressionmoves.”
The MSAC reviewed evidence that crizotinib confers an
incremental benefit in survival to patients testing positive for
ALK. The MSAC questioned the “biological plausibility” and
generalizability of the purported benefits of critizonib. In a review
of seven studies reporting on the overall survival rates in NSCLC
(including studies in patients with and without ALK rearrange-
ment), only one demonstrated a better prognosis. Given the lack
of demonstrative evidence suggesting a clear benefit, the MSAC
delayed action until a review of Australian patient data was
available.
Assessment outcome
The MSAC, the independent expert panel charged with reviewing
medical services and technology, concluded that although ALK-
FISH is an appropriate diagnostic tool the applicant did not
provide sufficient evidence to support practical implementation
of its proposal.
The acceptance of Abbott’s ALK-FISH test as the evidentiary
standard for determining ALK status was not disputed by the
MSAC. And when providing its recommendation to the Depart-
ment of Health, the MSAC did not refute any claims of diagnostic
value; rather it questioned (including but not limited to) 1) the
comparative health outcomes of ALK status, 2) the appropriate
position of ALK testing in the diagnostic sequence, and 3) optimal
patient population to be included for ALK testing.
MSAC’s review of ALK-FISH testing demonstrates that despite
real-world evidence (Abbott’s ALK-FISH diagnostic was used to
determine inclusion in crizotinib’s global registration studies),
the potential cost-impact to public health care budgets appears to
have had an impact on the committee’s recommendation.
Case of the CADTH Rapid Response on NIPT in Canada
HTA program and test evaluated
CADTH is a federal HTA agency in Canada responsible for
assessing novel technologies from a clinical and cost stand-
point. It helps decision makers keep pace with newly available
technologies by making recommendations on the basis of com-
prehensive reviews, but is not directly linked to reimbursement
outcomes. The case of the Rapid Assessment of NIPT demon-
strates how a structured review, focused on cost, of NIPT was
conducted and the outcomes that resulted [31]. The NIPT uses
cell-free DNA to determine the presence of aneuplody associated
with Down syndrome (trisomy 21), Edwards syndrome (trisomy
18), and Patau syndrome (trisomy 13). The NIPT has a false-
positive rate of about 0.2% and a detection rate of about 98% for
trisomy 21.Evaluation parameters
CADTH looked at the cost-effectiveness of the NIPT and the
evidence-based guidelines regarding its use. Four studies and one
evidence-based guideline were evaluated, after 260 citations were
reduced to 28 potential relevant articles. Of the economic studies,
three demonstrated increased costs and one decreased costs. Two
of the studies were from Canada, one from the United States, and
one from Australia and all were from the payer perspective. The
comparator used was screening strategies without the NIPT (i.e.,
amniocentesis). All cost-effectiveness studies included in the
review included clinical data as presented in previously pub-
lished articles. The assessment did not separately review the
clinical data. The rapid review urged interpreting the results with
caution given the discrepancy in results among reviewed studies.Assessment outcome
Universal screening with the NIPT was found not to be feasible
from a cost standpoint. However, use with high-risk women in
lieu of invasive testing (i.e., amniocentesis) was considered
feasible. The rapid assessment recognized that in addition to
their assessment, social and ethical issues may need to be
considered when incorporating the NIPT into screening and
diagnostic practice in Canada. The results of this report are not
binding to specific reimbursement outcomes.Discussion and Policy Recommendations
The case studies discussed provide illustrative examples of the
current evaluation processes and challenges for MDx. The three
examples have in common that evidence expectations varied
(clinical utility, patient outcomes, mortality, and quality of life)
and the selection and acceptance of evidence reviewed and
coverage decision making were not fully transparent. All
described HTA processes are lengthy from the perspective of
the respective manufacturers. Missions of HTA agencies vary as
well: Palmetto, for example, serves as a reimbursement gate-
keeper similar to Australia’s MSAC for diagnostics, whereas
NICE’s DAP assesses diagnostics in all phases of a product life
cycle that could already have reimbursement.
HTA organizations today do not provide consistent parame-
ters of acceptability in terms of clinical and analytic performance,
clinical utility, and economic impact. Current approaches have
also yet to consider, with the exception of screening tests in some
systems, whether different evidence expectations should be
applied to different test applications (i.e., risk assessment,
screening, diagnosis, treatment selection, and monitoring) or test
types (i.e., IVD vs. LDT). DAP’s review of EGFR-TK mutation tests
highlighted that there can be considerable uncertainty surround-
ing the actual performance of LDTs. For example, a local labo-
ratory that uses the same method may achieve similar
performance as the laboratory participating in the trial, but there
is no assurance that accuracy and reproducibility will be main-
tained in other laboratories performing the same test. In contrast,
regulatory-approved tests are uniformly validated and designed
to deliver consistent results across different laboratories. This
highlights the need for clear evidence guidelines that are sensi-
tive to the unique challenges in generating clinical evidence for
diagnostic tests.
Without such standards, HTA is left to subjective judgment
rather than objective assessment as to which tests meet, exceed,
or fail to meet standards. Clear and commonly accepted stand-
ards are needed across two dimensions: 1) study types that are
appropriate to demonstrate the value of MDx in the context of the
respective care pathway and 2) transparency of HTA processes,
including test selection for formal HTA and review criteria [4].
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between health systems represent major challenges for manu-
facturers in how best to generate appropriate evidence base that
can demonstrate molecular diagnostic value. Critics of the cur-
rent systems believe that the heterogeneity in HTA processes,
practices, and requirements for MDx results in fewer life-saving
or life-improving tests being broadly available to patients in need
[3,16,24,25]. Well-defined evidence requirements will inform evi-
dence development strategies for manufacturers and may help
attract investment into the diagnostics sector. Finally, clear
definition of the criteria used to assess the value of MDx and
clear links between meeting the criteria and reimbursement and
pricing outcomes are needed.
We recommend that HTA agencies incorporate several ele-
ments into molecular diagnostic HTAs to address the identified
challenges. See Table 4 for recommendations.1.T
d
1
2
3
4
5
6
7
8
9
H
laClear guidance as to the characteristics of MDx that will be
assessed, study design preferences and prioritization criteria
for HTA at a regional and/or national level;2. Early and ongoing opportunities for dialogue between health
care decision makers, heath technology assessors, payers,
clinicians, patients, and industry;3. Early guidance to manufacturers on evidence development,
comparator, or likelihood of an HTA for MDx;4. Opportunities for stakeholders to comment on evaluation
methods and evidence used to analyze the test;5. A checklist summarizing all required documents and com-
munication streams associated with the submission;6. An overview of the timing for HTA, and re-evaluation details
(the timing, requirements) if a negative assessment is
reached;7. Where possible, harmonized HTA requirements across
national/regional HTA groups to enhance timely access toable 4 – Recommended changes to molecular
iagnostic HTA processes.
. Clear guidance as to the characteristics of molecular diagnostics
that will be assessed, study design preferences and prioritization
criteria for HTA at a regional and/or national level
. Early and ongoing opportunities for dialogue between health care
decision makers, heath technology assessors, payers, clinicians,
patients, and industry
. Early guidance to manufacturers on evidence development,
comparator, or likelihood of an HTA for molecular diagnostics
. Opportunities for stakeholders to comment on evaluation
methods and evidence used to analyze the test
. A checklist summarizing all required documents and
communication streams associated with the submission
. An overview of the timing for HTA, and re-evaluation details (the
timing, requirements) if a negative assessment is reached
. Where possible, harmonized HTA requirements across national/
regional HTA groups to enhance timely access to molecular
diagnostics and streamline the process and reduce workload for
manufacturers and HTA bodies
. Clear definition of how criteria assessed in HTA translate into
molecular diagnostic pricing and reimbursement decision making
. Explicit recognition of and rationale for differential approaches to
LDTs vs. IVDs, and whether HTA-related reimbursement
outcomes are consistently applied to both
TA, health technology assessment; IVD, in vitro diagnostic; LDT,
boratory-developed test.MDx and streamline the process and reduce workload for
manufacturers and HTA bodies;8. Clear definition of how criteria assessed in HTA translate into
molecular diagnostic pricing and reimbursement decision
making; and9. Explicit recognition of and rationale for differential
approaches to LDTs versus IVDs, and whether HTA-related
reimbursement outcomes are consistently applied to both.
These proposed improvements would enhance the collabora-
tive nature and transparency of the process, which would be well
received by manufacturers and clinical stakeholders.
Ultimately, the HTA process for MDx is still evolving. There is
significant opportunity at regional, national, and international
levels to inform this development. Our proposed recommenda-
tions may help address major challenges that many systems
currently face by enhancing collaboration and transparency.
Establishing a true and open dialogue will mark a productive
next phase of HTA for diagnostics in which patients, clinicians,
payers, and health systems will benefit from timely access to
innovative and beneficial diagnostics.Acknowledgments
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